https://oncbrain.oncologytoolkit.com/ AI-summarized oncology meeting studies, curated by a subspecialist. One item per study. en Mon, 01 Jun 2026 00:00:00 GMT https://oncbrain.oncologytoolkit.com/2026-06-01/#ctdna-rectal-nonop-surveillance https://oncbrain.oncologytoolkit.com/2026-06-01/#ctdna-rectal-nonop-surveillance Mon, 01 Jun 2026 00:00:00 GMT lower-gi [Early signal] ctDNA sensitivity only 41% for local regrowth vs 74% for distant mets in 110 NOM rectal pts; risk stratifies but cannot replace imaging. Eligible: Stage I-III MSS rectal, cCR/nCR after NAT, undergoing NOM https://oncbrain.oncologytoolkit.com/2026-05-22/#dbcg-imn2 https://oncbrain.oncologytoolkit.com/2026-05-22/#dbcg-imn2 Fri, 22 May 2026 00:00:00 GMT breast [Confirmatory] 15-yr OS 65.0% vs 60.8%, HR 0.85 (0.76-0.94), p=0.0016 favoring IMNI in node-positive breast cancer with modern systemic therapy, N=4541. Eligible: Node-positive breast cancer, adjuvant RT, taxane/trastuzumab/AI systemic therapy https://oncbrain.oncologytoolkit.com/2026-05-17/#dutch-breast-boost-systemic-era https://oncbrain.oncologytoolkit.com/2026-05-17/#dutch-breast-boost-systemic-era Sun, 17 May 2026 00:00:00 GMT breast [Early signal] 10-yr IBTR 1.2% with or without boost in 0-2 risk-factor BCT pts; boost omission appears safe in modern systemic era. Eligible: Early-stage breast cancer, BCT + WBRT, modern systemic therapy era, stratified b https://oncbrain.oncologytoolkit.com/2026-05-17/#oligocare https://oncbrain.oncologytoolkit.com/2026-05-17/#oligocare Sun, 17 May 2026 00:00:00 GMT oligo-mets [Early signal] 88.6% local control at 3yrs across 2447 pts; CRC shows worst local control despite highest delivered dose. Eligible: Oligometastatic solid tumors, multiple histologies, 1-5 mets, SABR-eligible